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Abstract
Nonmuscle myosin heavy chain IIA (NMMHCIIA) encoded by MYH9 is associated with autosomal dominantly inherited
diseases called MYH9 disorders. MYH9 disorders are characterized by macrothrombocytopenia and very characteristic
inclusion bodies in granulocytes. MYH9 disorders frequently cause nephritis, sensorineural hearing disability and cataracts.
One of the most common and deleterious mutations causing these disorders is the R702C missense mutation. We
generated knock-in mice expressing the Myh9 R702C mutation. R702C knock-in hetero mice (R702C+/2 mice) showed
macrothrombocytopenia. We studied megakaryopoiesis of cultured fetal liver cells of R702C+/2 mice and found that
proplatelet formation was impaired: the number of proplatelet tips was decreased, proplatelet size was increased, and
proplatelet shafts were short and enlarged. Although granulocyte inclusion bodies were not visible by May–Grünwald
Giemsa staining, immunofluorescence analysis indicated that NMMHCIIA proteins aggregated and accumulated in the
granulocyte cytoplasm. In other organs, R702C+/2 mice displayed albuminuria which increased with age. Renal pathology
examination revealed glomerulosclerosis. Sensory hearing loss was indicated by lowered auditory brainstem
response. These findings indicate that Myh9 R702C knock-in mice mirror features of human MYH9 disorders arising
from the R702C mutation.
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Introduction
May-Hegglin Anomaly (MHA) is an autosomal-dominant
inherited disorder characterized by macrothrombocytopenia and
Döhle body-like cytoplasmic inclusion bodies in granulocytes. Ten
years ago, we and others showed that MYH9, which encodes non-
muscle myosin heavy chain IIA (NMMHCIIA), is mutated in this
disorder [1–3]. MYH9 is expressed in hematological cells, as well
as in kidney, cochlea and lens cells. Thus, patients with a MYH9
mutation often suffer from nephritis, deafness and cataracts. A new
disease entity, MYH9 disorders, has been proposed to encompass a
wide variety of clinical phenotypes [4,5]. To date, more than 40
MYH9 mutations have been reported. Among these, the R702C
mutation is associated with the development of nephritis and
hearing loss in young patients [6–8].
Myh9 homozygous knockout mice die at the embryonic stage,
while heterozygous knockout mice are phenotypically normal
[9,10]. Thus, simple haploinsufficiency is not the pathogenetic
mechanism underlying MYH9 disorders. Zhang et al. reported
three mutant Myh9 mouse lines, D1424N and E1841K in the tail
domain and R702C in the head domain, that reproduced clinical
phenotypes in mice. However, R702C hetero mice were generated
by disrupting Myh9 exon 2 and replacing it with human
NMMHCIIA harboring R702C fused to eGFP (GFP-R702C
mice) [11]. In human MYH9 disorders, it is known that R702C
mutation shows more severe macrothrombocytopenia than other
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mutations [8], while such mutations as R702C in the head
domain, are known to induce severe nephritis [6]. However, the
clinical phenotypes of GFP-R702C mice were weaker than
anticipated. Here, we have employed a different knock-in strategy
with GFP-R702C mice to generate and characterize mice
expressing the R702C mutation in the mouse gene. The DNA
construct was intended to replace the endogenous Myh9 gene with
an R702C mutation. A Neo marker inserted into the intron
upstream of Myh9 exon 15 is flanked, by loxP sequence, then
removed by crossing with a CAG-Cre mouse. Thus we successfully
left the Myh9 DNA sequence as intact as possible, such that
R702C+/2 mice have only one amino acid substitution of
R702C.
The established R702C knock-in hetero mice (R702C+/2
mice) are expected to fully express the hematological/non-
hematological phenotypes found in patients with MYH9 disorders
as compared with GFP-R702C mice.
Materials and Methods
Construction of the Myh9 R702C knock-in vector
A genomic DNA fragment containing murine Myh9 (C57BL/6J,
Accession number NC_000081) was obtained by PCR and used as
a probe to isolate a genomic clone containing a segment of Myh9
from a 129SVJ lambda FIX II genomic library (Stratagene, La
Jolla, CA, USA). The targeting vector (pMulti ND-
1.0_Myh9R702Cneo) was constructed from basic vector pMulti
ND-1.0 [12]. The MYh9 fragments consisted of a BstXI/BglII
fragment as the 59 arm and a BglII/Sau3AI fragment as the 39 arm
(Figure 1A). We introduced the R702C mutation into the 39 arm
and an additional silent mutation to create a diagnostic NdeI site.
Generation of Targeted Mice
Linearized targeting vector was electroporated into D3 ES cells
derived from 129Sv and screened for neomycin resistance. Two
homologous recombinant ES clones were independently injected
into C57B6 blastocysts to generate chimeric mice. Male chimera
derived from one ES clone transmitted the recombinant allele to
the next generation (Myh9R702Cneo). The loxP-neo cassette was
removed by crossing the heterozygous mice with a CAG-Cre
deleter mouse strain that constitutively expresses Cre recombinase
to yield heterozygous knock-in mice (R702C+/2 mice). Long-
range PCRs were performed using the 59 external sense primer
(59-ACAGGACCCAGCCACCATACAA) and the 39 external
antisense primer (59-GGCTGTAGATGGCTTTTGTG), fol-
lowed by NdeI digestion to confirm the mutant (Figure 1C).
All research procedures involving animals were performed in
accordance with the Laboratory Animals Welfare Act, the Guide for
the Care and Use of Laboratory Animals, and the Guidelines and
Policies for Rodent Experiments provided by the Institutional
Animal Care and Use Committee (IACUC) at the Nagoya
University Graduate School of Medicine and were reviewed and
approved by the IACUC. The protocol was approved by the
committee on the Ethics of Animal experiments of the Nagoya
University Graduate School of Medicine (Permit Number:25016).
Hematological analysis
Whole blood was obtained from the aorta. Complete blood cell
counts were determined using an automated blood cell analyzer
(SE9000; Sysmex, Kobe, Japan). Blood smears were stained with
May–Grünwald Giemsa (MGG) solution for immunofluorescence
analysis. Platelet counts of R702C+/2 mice were determined
manually from MGG-stained smears. Bone marrow cells from
dissected femurs were subjected to hematoxylin-eosin (HE)
staining and anti-CD41 and NMMHCIIA immunostaining.
NMMHCIIA immunostaining
Immunofluorescence analysis of granulocyte NMMHCIIA was
performed as described previously [13]. Methanol-fixed and
acetone-permeabilized blood smears were incubated with anti-
NMMHCIIA antibody (BT561; Biomedical Technologies Inc.,
Stoughton, MA, USA) and reacted with Alexa Fluor 555-labeled
goat anti-rabbit IgG (Invitrogen, San Diego, CA, USA). Stained
cells were examined under a fluorescence microscope (BX50;
Olympus, Tokyo, Japan).
Tail bleeding time measurement
Mice were anesthetized, the tail was cut 5 mm from the tip, and
the tail was immediately immersed into a tube filled with 1 mL
saline at 37uC. Bleeding time was defined as the time required for
bleeding to stop.
Clot retraction
Blood was obtained from the aorta of anesthetized mice, and
was immediately transferred to a tube containing EDTA. Platelet-
rich plasma (PRP) was collected from the supernatant after 40 min
of stationary incubation in the tube, and then platelet-poor plasma
(PPP) was obtained by centrifugation at 706g for 5 minutes with
no brake. Platelet number of PRP was adjusted to 306104/ml by
dilution with PPP. Mouse erythrocytes (2 mL) were obtained from
the centrifuged sediment and added to the PRP suspension
(200 mL). Finally, thrombin (final concentration, 10 U/mL;
Sigma-Aldrich, Tokyo, Japan) was added in the presence of
20 mM CaCl2 and incubated for up to 2 hours at 37uC.
Culture of fetal liver-derived megakaryocytes
Fetal liver cells were harvested from embryonic day 13.5
embryos and cultured in Dulbecco’s modified Eagle medium
supplemented with 10% fetal calf serum (FCS) and 50 ng/mL
human thrombopoietin, as described previously [14]. Proplatelet
formation was monitored in suspension by inverted fluorescence
microscopy (IX71; Olympus, Japan), or by cytospin preparations
stained with MGG and immunostained with anti-CD41 or
NMMHCIIA.
Evaluation of albuminuria and hematuria
Spot urine samples free of fecal contamination were collected
and the concentration of albumin was quantitatively determined
using an ELISA kit (AlbuwellM; Exocell, Philadelphia, PA, USA).
Urine samples were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis on 4%–12% gradient acrylam-
ide slab gels (Invitrogen, San Diego, CA, USA) under reducing
conditions, and gels were then stained with Coomassie Brilliant
Blue R-250.
Urine hematuria was analyzed at the age of 20 weeks by using
conventional strip method based on the peroxidase activity of
hemoglobin (Eiken Chemical, Tochigi, Japan).
Histological evaluation of kidney
Tissue for light microscopy was fixed in 4% paraformaldehyde
phosphate buffer solution, processed, then embedded in paraffin.
Three-micrometer sections were stained with periodic acid-
methenamine-silver (PAM).
In order to determine the extent of glomerulosclerosis, 10 fields
were randomly selected from the renal cortex. The number of
glomeruli was counted under a microscope at 6100 magnification
A New Mice Model of MYH9 Disorders
PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e71187
Figure 1. Myh9 R702C knock-in strategy. A) Targeting strategy for R702C knock-in mutation of the murine Myh9 gene. The targeting vector
pMulti-ND1.0_Myh9neo, the wild-type Myh9 allele and the targeted allele before (Myh9neo) and after Cre-mediated excitation of the loxP franked neo
cassette (Myh9mt) are schematically represented. The targeting vector also contains the Diphtheria toxin fragment A (DTA) gene outside the flanking
homologies. Black boxes in the genomic structures represent exon sequences; the asterisk on exon 16 denotes the R702C mutation; the underlined N
(NdeI) denotes the extra diagnostic restriction site created by silent mutation. The expected restriction fragments of the genotyping PCR products are
indicated with their relative size accompanied with solid lines. The black box above the wild-type gene represents the 59 probe used for Southern
blot analysis. The open arrowheads under the gene represent the primers used for long-PCR genotyping. (B, C) Confirmation at the DNA level of
correct targeting of the Myh9 gene. Correct homologous recombination as identified by an additional 4.8-kb band in Southern blot analysis of HindIII
digested genomic DNA with the 59 probe, as well as by a 3.8 kb targeted fragment in long-PCR products digested with NdeI (B). Correct Cre-mediated
excitation of the loxP franked neo cassette as confirmed by the appearance of a 2.4 kb recombined instead of 3.8 kb targeted fragment in long-PCR
products digested with NdeI (C).
doi:10.1371/journal.pone.0071187.g001
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(Olympus, Tokyo, Japan), and the number of glomeruli per field
was converted number to per mm2. The percentage of glomeruli
with sclerosis was determined based on the ratio of glomeruli with
sclerosis/total glomeruli.
For electron microscopy, small pieces of kidney tissue were fixed
in 2.5% glutaraldehyde for 2 hours at 4uC, osmicated, and then
embedded in Epon 812 (Nisshin EM, Tokyo, Japan). Ultrathin
sections were observed under a JEM-2010 electron microscope
(JEOL, Tokyo, Japan).
Measurement of auditory brain stem response (ABR)
Mice were anesthetized, and then needle electrodes were
inserted into the vertex (positive), auricle of the right ear (negative)
and auricle of the left ear (ground). Tone bursts of 1-ms duration
Figure 2. Macrothrombocytopenia and abnormal NMMHCIIA accumulation in granulocytes. R702C+/2 mice exhibited decreased
platelet count (mean6SD, C57BL/6j: 121261466109/L vs. R702C+/2: 3426496109/L) (n = 10) (A). Platelet size was evaluated by measuring platelet
diameter (mean6SD: C57BL/6j: 1.5260.29 mm vs. R702C+/2: 3.6560.56 mm) (n = 10) (B). Most R702C+/2 mice had a bleed time comparable to WT
mice, although several displayed prolonged bleed times (n = 10) (C). Clot retraction was not impaired in R702C+/2 mice. Data are representative of
three experiments (D). There were no abnormalities in granulocytes and no granulocyte inclusion bodies were visible following May–Grünwald
Giemsa (MGG) staining (E) (F). Immunofluorescence analysis showed that NMMHCIIA aggregated and accumulated in the granulocyte cytoplasm of
R702C+/2 mice (G)(H).
doi:10.1371/journal.pone.0071187.g002
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with a rise and fall time of 0.1 ms at frequencies of 8, 12, 16 and
20 kHz were produced using a sound stimulator (RP2.1; Tucker-
Davis Technology Co., Alachua, FL, USA) and a speaker (ES-1;
Tucker-Davis Technology Co.) connected to the right ear canal. A
total of 512 tone-burst-evoked responses were obtained with
amplifier filters set below 100 Hz and above 3 kHz. The mean of
the amplified responses was determined using the program
PowerLab 4/20 (ADInstruments, Castle Hill, Australia) and
displayed on a monitor. Auditory brain stem responses were
obtained by decreasing the stimuli in 5-dB steps from a maximum
intensity of 100 dB sound pressure level.
Results
Generation of R702C+/2 mice
In order to investigate the molecular and pathological
mechanisms underlying human MYH9 disorders, we introduced
a Myh9 R702C mutation into the mouse genome using a knock-in
approach (Figure 1). Germline transmission of the targeted allele
was obtained and identified by Southern blot and long-range PCR
analysis. The targeted embryonic stem cells were injected into
blastocysts and implanted into surrogate females to generate Myh9
R702C knock-in chimeric mice. These mice were crossed with
B6.Cg-Tg(CAG-cre/Esr1*)5Amc/J (The Jackson Laboratory, Bar
Harbor, ME, USA) to excise the floxed Neo resistance cassette.
R702C+/2 mice had an extremely low birthrate: only 12.0%
by crossing R702C+/2 mice and C57BL/6j mice (Table S1).
Heterozygous mating yielded no homozygous mutant offspring,
suggesting that this is an embryonic lethal phenotype, as in the
absence of Myh9 [10]. We verified that R702C homozygous mice
were alive at E12.5, but no living embryos were detected at E18.5
(Table S1).
R702C+/2mice display macrothrombocytopenia
All R702C+/2 mice exhibited lower platelet counts than
C57BL/6j mice (wild-type mice unrelated to R702C +/2 mice:
WT mice). An average platelet count represented around 30% of
C57BL/6j mice (Figure 2A). The diameter of platelets from
R702C+/2 mice was more than twice that from WT mice
(Figure 2B).
R702C+/2 mice are equivalent to WT mice in bleeding
time and clot retraction
R702C+/2 mice have no spontaneous bleeding tendency.
Three out of 10 R702C+/2 mice displayed prolonged bleeding
time, but most bled for approximately the same length of time as
WT mice (Figure 2C). Clot retraction was slightly reduced in
R702C+/2 mice, but there were no significant differences when
compared with WT mice (Figure 2D).
Abnormal localization of NMMHCIIA in granulocytes
Although the presence of granulocyte inclusion bodies in
conventionally stained blood smears is the most characteristic
feature of human MYH9 disorders, R702 mutations are associated
with faint or invisible inclusion bodies [8]. Inclusion bodies were
also invisible in R702C+/2 mice (Figure 2E and F). However,
immunofluorescence analysis for NMMHCIIA revealed an
abnormal localization of the protein that we define as type II
small punctuated or granular cytoplasmic granules [8] (Figure 2G
and H). This indicates that mutant NMMHCIIA displays the same
aggregation-prone features in humans and in mice [13].
Abnormal proplatelet formation is present in cultured
fetal liver-derived megakaryocytes from R702C+/2 mice
We examined the morphology of bone marrow megakaryocytes
by MGG staining. Although megakaryocyte number was in-
creased (Figure S1), their morphology was comparable to that of
WT mice (Figure 3A and B) and showed no abnormal pattern of
NMMHCIIA localization (Figure 3C and D).
We evaluated proplatelet formation using cultured megakaryo-
cytes. The percentage of megakaryocytes with extended proplate-
lets was significantly lower in R702C+/2 mice (Figure S2). In WT
mice, the proplatelet shaft that extends from the cell spindle causes
the formation of numerous proplatelet beads. R702C+/2 mice
had shorter and thicker shafts and fewer and larger proplatelet
beads when compared to WT mice (Figure 3E–H). These results
are consistent with thrombocytopenia and increased platelet size in
Figure 3. Abnormal megakaryocytopoiesis. In hematoxylin-eosin
staining, the morphology of megakaryocyte in R702C+/2 mice was not
different from that of WT mice (A) (B). There were no significant
differences in the distribution of NMMHCIIA between R702C+/2 mice
and WT mice by immunostaining (C) (D). Proplatelet formation was
explored by cultured fetal liver cells. In WT mice, the proplatelet shaft
extends from the cell spindle, leading to the formation of proplatelet
beads. R702C+/2 mice had shorter and thicker shafts when compared
with WT mice, and the proplatelet beads were fewer and larger than
those of WT mice. MKs were stained with MGG (E) (F) or were observed
using CD41 immunofluorescence (G) (H).
doi:10.1371/journal.pone.0071187.g003
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patients with MYH9 disorders, indicating that the heterozygous
R702C mutation leads to abnormal proplatelet formation.
R702C+/2 mice display progressive albuminuria and
glomerulosclerosis
R702C+/2 mice showed progressive albuminuria with age,
while WT mice had trace amounts of urine albumin between 5–20
weeks (Figure 4A and B). At five weeks of age, all R702C+/2 mice
developed severe albuminuria. However, R702C+/2 mice
displayed little hematuria from 7 to 20 weeks of age (Table 1).
Kidney pathology from R702C+/2 mice was grossly abnormal.
Pathological examination by light microscopy revealed glomerular
sclerosis. Global glomerulosclerosis was mainly seen (Figure 4C
and E), and some glomeruli displayed segmental glomerulosclero-
sis (Figure 4C and F). Electron microscopy showed podocyte foot
process effacement (Figure 4G and H) characteristic of podocyte
injury. These findings are compatible with human patients with
R702C mutations [7]. Quantification of the percentage of
glomeruli with sclerosis was also performed (Table 2). Glomerular
changes ranging from mild segmental sclerosis to global sclerosis
were observed in all regions of the renal cortex, and accounted for
43.4% of total glomeruli (Table 2).
Some R702C+/2 mice exhibit sensory deafness
The mean level of ABR thresholds obtained at 2, 4, 8 and
16 KHz were plotted (Figure 5). WT mice showed normal
thresholds for evoke stimuli, whereas the thresholds of ABR in
R702C+/2 mice were significantly higher at all frequencies. No
morphological changes in the inner ears of R702C+/2 mice were
observed by light or electron microscopy (data not shown).
R702C+/2 mice do not exhibit cataracts
The lenses of six of eight R702C+/2 mice showed vacuole
formation in the lens fibra, a change characteristic of cataracts
(Figure S3). However, the degree of vacuolation was not severe,
and indeed, four of six age-matched WT mice also showed similar
pathological findings (data not shown).
Discussion
Zhang et al. generated and characterized three mutant Myh9
mouse lines: D1424N, E1841K and R702C [11]. D1424N and
E1841K mice were generated using the conventional knock-in
technique that we employed, but their R702C hetero mice were
generated by disrupting the Myh9 exon 2 and replacing it with
human NMMHCIIA fused to eGFP (GFP-R702C mice). On the
whole, our R702C+/2 mice had clinical phenotypes similar to
GFP-R702C hetero mice and both transgenic mouse models
reproduced clinical characteristics of MYH9 disorders. However,
the differences in knock-in strategies had lead to differences in
intensity of phenocopy expression. Our mice were more definitive
in phenocopy than GFP-R702C hetero mice (Table S2).
Especially, R702C+/2 mice displayed lower platelet number
than D1424N, E1841K and GFP-R702C hetero mice (Table S2).
Especially, platelet count was similar to that of megakaryocyte-
specific Myh9 knockout mice with no NMMHCIIA expression in
megakaryocytes (MYH9D mice) [15]. Although platelet diameters
were measured under different conditions, platelets of R702C+/2
mice were larger than in GFP-R702C hetero mice (Table S2). In
humans, it has been reported that R702 mutations provide
significantly larger platelets than other mutations located in the tail
domain [8]. R702C+/2 mice also displayed larger platelet
diameters than D1424N and E1841K hetero mice (Table S2),
suggesting that our R702C+/2 mice mirror the platelet pheno-
type found in human MYH9 disorders.
The number of megakaryocytes in R702C+/2 mice was
increased when compared to that of WT mice (Figure S1). This
might be due to reactive thrombocytopoiesis arising from
decreased platelet number. The megakaryocyte morphology of
R702C+/2 mice was similar to that of WT mice (Figure 3A and
B) and there were no significant differences in NMMHCIIA
localization between R702C+/2 and WT mice. However, in
human subjects, immunofluorescence analysis using antibodies
specific for mutant NMMHCIIA revealed abnormal NMMHCIIA
localization in megakaryocytes derived from peripheral blood
CD34+ cells of patients with MYH9 disorders, and these were
Figure 4. Abnormal kidney function. Coomassie blue-stained SDS-PAGE gel of urine samples from 5 and 20 week old mice (A). Albuminuria was
also measured at 5, 10, 15 and 20 weeks using an ELISA kit (AlbuwellM, Exocell) (n = 6) (B). These results show that, while WT mice had little
albuminuria at any age, R702C+/2 mice had significant albuminuria from the age of 5 weeks. This progressive albuminuria was observed in all
R702C+/2 mice. Pathologic confirmation of albuminuria was obtained by light and electron microscopy of renal specimens from 20-week-old
R702C+/2 mice and WT mice. Light microscopy samples were stained with Periodic acid-methenamin (PAM) and were observed at 100-fold
magnification (C) (D) and 630-fold magnification (E) (F) (G). R702C+/2 mice displayed significant glomerulosclerosis (D), primarily global
glomerulosclerosis (indicated by white arrow in D and magnified on (G)) and some segmental glomerulosclerosis (indicated by black arrow in D and
magnified on (F)). (C) and (E) are normal controls. Electron microscopic analysis was performed at 3000-fold magnification (H) (I). Transmission
electron microscopy revealed foot process effacement (I). (H) is normal control.
doi:10.1371/journal.pone.0071187.g004
Table 1. Urine examination by urinary test strip.
R702C +/2 (7 weeks) R702C +/2 (20 weeks) C57BL/6j (20 weeks)
1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6
Hematuria 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Proteinuria 6 ++ + + ++ + +++ + +++ ++ +++ ++ 6 2 2 2 6 6
Urinal sugar 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
PH 6 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 5 7
Hematuria: 2 means RBC,10/ml, Hb,0.03 mg/dl.
Proteinuria: 6:15, +:30, ++:100, +++:300 (mg/dl).
Urinal sugar: 6:50, +:100, ++:250, +++:500 (mg/dl).
doi:10.1371/journal.pone.0071187.t001
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coarsely and heterogeneously distributed in MYH9 disorders [16].
This observation indicates that the normal distribution of
NMMHCIIA displayed by antibodies against wild-type
NMMHCIIA does not necessarily imply that abnormal
NMMHCIIA harboring R702C mutation has a normal distribu-
tion in megakaryocytes.
It has been proposed that myosin activation through the Rho-
ROCK-myosin light chain (MLC)-myosinII pathway could act as
a negative regulator of proplatelet formation [17,18].
NMMHCIIA produced by mice carrying the R702C mutation
has weaker affinity for binding ATP and actin than NMMHCIIA
in wild-type mice [19]. NMMHCIIA from R702C mice shows a
dominant negative effect; proplatelet formation was impaired
more severely in R702C+/2 mice than in Myh9 knockout hetero
mice showing characteristics of haploinsufficiency [10,15]. Con-
sequently, MYH9 disorders may cause premature platelets to be
released into the bone marrow due to end stage defects in mature
megakaryocytes.
R702C+/2 mice showed no obvious changes in bleeding time
or clot retraction when compared to WT mice. In human MYH9
disorders, mutant NMMHCIIA is not transported from megakar-
yocytes into platelets and it is not present within platelets [16].
Patients with MYH9 disorders usually exhibit normal primary
hemostasis, perhaps because their platelets retain normal function
due to residual normal NMMHCIIA. This may be also the case in
R702C+/2 mice.
In the kidney, R702C+/2 mice displayed significant age-
dependent albuminuria and glomerulosclerosis. One characteristic
was that R702C+/2 mice had more global glomerulosclerosis
than segmental sclerosis. However, human patients carrying the
R702 mutations were reported to display focal segmental
glomerulosclerosis (FSGS) [7]. Thus, there were some differences
in renal pathogenesis between R702C+/2 mice and human
patients. In addition, R702C+/2 mice displayed little hematuria
(Table S1). It was unlikely in view of severe glomerulosclerosis, as
human FSGS is known to present with microscopic hematuria.
Concerning that our urine test papers were known to work on
mouse urine [20], there appears to be some species differences in
glomerulopathy caused by R702C mutation. In this context, GFP-
R702C hetero mice was reported to display FSGS [11] and this
pathological difference may be also caused by a variation in knock-
in construct or expression of human/mouse mutated genes.
Johnstone et al. hypothesized that MYH9 dysfunction in
podocytes causes kidney disease in patients with MYH9 disorders.
However, podocyte-specific deletion of MYH9 in C57BL/6 mice
did not evoke kidney dysfunction, although these mice were
predisposed to focal and segmental glomerulosclerosis with
glomerular changes ranging from mild segmental sclerosis to
severe global sclerosis after additional treatment with doxorubicin,
used to stress podocytes [21]. These results indicate that overt
glomerulosclerosis cannot be caused solely by deletion of Myh9 in
podocytes in mice. NMMHCIIA encoded by MYH9 is expressed
in podocytes and other structures in kidney, such as renal tubular
cells, endothelial cells and endocapillary cells [7,21,22]. Thus,
absence of NMMHCIIA in structures other than podocytes could
affect the development of glomerulosclerosis. It is also known that
FSGS involves podocytes, as all identified causative genes in
hereditary FSGS are located in podocytes [23]. This factor
suggests that the R702C mutation that acts on podocytes in a
dominant negatively fashion plays an important role in the
development of glomerulosclerosis.
Table 2. Percentage of glomeruli with sclerosis.
C57BL/6j (20 weeks) R702C+/2 mice (20 weeks)

















Average Glomerulus with Sclerosis
(/mm2)
0.0 0.0 24.8 23.6 16.9 10.1 19.9


























Average Total Glomerulus (/mm2) 33.8 34.1 49.0 48.4 40.0 40.3 38.8
Ratio of Glomerulus with Sclerosis (%) 0.0 0.0 50.6 48.8 42.3 25.2 50.0
Mean ratio of glomerulus with sclerosis (%): 43.4% (n = 5).
doi:10.1371/journal.pone.0071187.t002
Figure 5. Auditory Brain-stem Response (ABR). ABR measurement
in R702C+/2 mice. Means and standard deviations of ABR thresholds (in
dB SPL) in R702C+/2 mice and WT mice. ABRs were measured in 10
R702C+/2 mice and five WT mice aged approximately 20 weeks, as
described in Materials and Methods.
doi:10.1371/journal.pone.0071187.g005
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In patients with the R702C mutation, granulocyte inclusion
bodies are invisible or inconspicuous by MGG staining, although
immunofluorescence analysis shows that NMMHCIIA proteins
aggregate and accumulate within the granulocyte cytoplasm
[8,16]. R702C+/2 mice showed similar characteristics.
Patients with the R702C mutation develop sensory deafness by
the age of 30 [7]. ABR experiments showed that around 40% of
R702C+/2 mice displayed severe deafness, although no abnor-
malities in cochlear cells were observed by light or electron
microscopy (data not shown). Further investigations into how
MYH9 dysfunction results in deafness are required.
R702C+/2 mice and WT mice showed similar incidences of
cataracts; thus, R702C+/2 mice cannot be characterized by the
development of cataracts. It is uncertain whether patients with the
R702C mutation are predisposed to developing cataracts.
It is unclear why R702C homozygous mice die at the embryonic
stage. GFP-R702C mice died at E11.5 because of defects in
placental development [11], but R702C+/2 mice at E18.5 show
no abnormalities in the placenta or umbilical cord (data not
shown). Such difference is another example of different construct
design, but it requires further exploration to understand how
R702C influences embryonic development.
In summary, clinical phenotypes were expressed more grossly in
mice by changing the knock-in strategy to exactly represent the
phenotype of R702C mutation. Detailed analysis of R702C+/2
mice suggested that this mutation causes more severe macro-
thrombocytopenia and nephritis than tail domain mutations in
mice, as well as in humans. Thus, R702C+/2 mice will aid our
understanding of this complicated human disease.
Supporting Information
Figure S1 The number of megakaryocyte. Sections of bone
marrow samples collected from age matched WT and R702C+/2
mice were stained with hematoxylin-eosin. The number of
megakaryocytes was counted in 5 fields of view and represent
mean6SD (n = 3). Megakaryocyte numbers were increased in
R702C+/2 mice.
(PPT)
Figure S2 Megakaryocytes with proplatelets. The percentage of
megakaryocytes producing proplatelets was determined by the
number of megakariocytes with proplatelets. Fetal liver-derived
megakaryocytes were examined in suspension cultures. The
number of megakaryocytes was counted under a microscope.
(PPT)
Figure S3 Vacuolation of lens fibra (cataract). The pathology of
lens of R702C+/2 mice and WT mice at 20 weeks stained with
Hematoxilin-Eosin. Several samples of R702C+/2mice show
vacuolation of lens fibra just below the epithelium lentis.
(PPT)
Table S1 Genotypes of offspring from heterozygous mating.
(PPT)
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